Market Size of Spain Nuclear Imaging Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Market Size (2024) | USD 164.51 Million |
Market Size (2029) | USD 188.68 Million |
CAGR (2024 - 2029) | 2.78 % |
Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Spain Nuclear Imaging Market Analysis
The Spain Nuclear Imaging Market size is estimated at USD 164.51 million in 2024, and is expected to reach USD 188.68 million by 2029, growing at a CAGR of 2.78% during the forecast period (2024-2029).
COVID-19 had an adverse effect on Spain nuclear imaging market. Various research studies have been published to provide insight into the effects. According to a June 2021 article in the European Union of Private Hospitals, general hospitals in Spain added 5,000 new professionals while increasing their staff by 6% in 2020 compared to 2019. This was due to the country's hospital admission rate, which was about 33% for COVID-19 patients. However, the issue with healthcare professionals was particularly serious because, at any given moment, about 26.3% of the staff was discovered to be COVID positive. Numerous industry participants now have the chance to improve their positions through the introduction of new goods or the creation of partnerships thanks to COVID-19. For instance, the radiotherapy staff at the HC Cancer Center began administering the first Synchrony treatments in Spain in July 2021. This cutting-edge technology combines TomoTherapy's helical movement with a tumor-tracking system, enabling the application of the best dose with submillimeter precision while preserving as much healthy tissue as possible. This leads to a higher quality of life and more effective radiation treatment with fewer side effects. Thus, the market for nuclear imaging in Spain was impacted by the aforementioned causes.
Technological improvements, and expanding diagnostic applications in various diseases such as cancer are all factors driving the market's growth in Spain. According to projections from the Global Cancer Observatory, Spain is expected to see 113,054 cancer deaths and 282,421 newly diagnosed cancer cases in 2020. One of the main factors driving the market is the increase in the incidence of heart diseases and cancer. Cancer and heart conditions can be effectively treated with nuclear medicine. The diagnosis of hepatocellular carcinoma metastases is more precise with PSMA (prostate-specific membrane antigen) PET/CT than with standard CT, according to a research published in the September 2021 issue of The Journal of Nuclear Medicine. With more precise imaging for patient staging, medical professionals can spot patients early on who can benefit from specific therapies, including chemotherapy, which affects survival and quality of life. While the country's increased product releases are anticipated to boost the market. For instance, in the Spanish areas of Andalusia, Aragon, Catalonia, La Rioja, Murcia, and Madrid, Koninklijke Philips N.V. and Viamed hospital group joined in June 2020 to deliver sophisticated diagnostic imaging solutions to their 11 hospitals and 15 healthcare centres. Thus, the abovementioned factors are likely to increase the market growth.
However, the lack of proper reimbursement and stringent regulatory approval procedures, and the high cost of equipment, are expected to impede the market growth in Spain.
Spain Nuclear Imaging Industry Segmentation
As per the scope of the report, nuclear medicine imaging procedures are non-invasive, with the exception of intravenous injections, and are usually painless medical tests that help physicians diagnose and evaluate medical conditions. These imaging scans use radioactive materials called radiopharmaceuticals or radiotracers. These radiopharmaceuticals are used in diagnosis and therapeutics. They are small substances that contain a radioactive substance that is used in the treatment of cancer, and cardiac and neurological disorders. Spain Nuclear Imaging Market is segmented by Product (Equipment, and Diagnostic Radioisotope (SPECT Radioisotopes, and PET Radioisotopes), Application (SPECT Application (Cardiology, Neurology, Thyroid, and Other SPECT Applications), and PET Application (Oncology, Cardiology, Neurology, and Other PET Applications). The report offers the value (in USD million) for the above segments.
By Product | ||||
Equipment | ||||
|
By Application | ||||||
| ||||||
|
Spain Nuclear Imaging Market Size Summary
The Spain nuclear imaging market is poised for growth, driven by technological advancements and the increasing prevalence of diseases such as cancer and heart conditions. The market is experiencing a resurgence following the challenges posed by the COVID-19 pandemic, which had initially disrupted operations and strained healthcare resources. The introduction of innovative technologies, such as the Synchrony treatments at the HC Cancer Center, highlights the sector's resilience and adaptability. These advancements are enhancing the precision of treatments and improving patient outcomes, thereby fueling market expansion. Additionally, collaborations between key industry players, such as the partnership between Koninklijke Philips N.V. and the Viamed hospital group, are facilitating the deployment of advanced diagnostic imaging solutions across various regions in Spain, further contributing to market growth.
Despite the positive outlook, the market faces challenges, including high equipment costs, stringent regulatory approvals, and inadequate reimbursement frameworks. However, the growing adoption of SPECT and PET scanners for disease diagnosis and the rising incidence of chronic disorders are mitigating these challenges. The prevalence of thyroid cancer in Spain is expected to drive demand for SPECT imaging, while the increasing number of PET scans performed underscores the need for sophisticated imaging technologies. Key market players, including Canon Inc., GE Healthcare, and Siemens Healthineers AG, are actively participating in initiatives to advance nuclear imaging capabilities. Projects like the High Sensitivity Molecular Imaging project IMAS, supported by GE Healthcare, are set to enhance the market's growth trajectory by developing innovative imaging solutions.
Spain Nuclear Imaging Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Prevalence of Chronic Diseases
-
1.2.2 Rising Geriatric Population
-
1.2.3 Increasing Technological Advancements
-
-
1.3 Market Restraints
-
1.3.1 Lack Of Proper Reimbursement And Stringent Regulatory Approval Procedures
-
1.3.2 High Cost of Equipment
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Product
-
2.1.1 Equipment
-
2.1.2 Diagnostic Radioisotope
-
2.1.2.1 SPECT Radioisotopes
-
2.1.2.2 PET Radioisotopes
-
-
-
2.2 By Application
-
2.2.1 SPECT Application
-
2.2.1.1 Cardiology
-
2.2.1.2 Neurology
-
2.2.1.3 Thyroid
-
2.2.1.4 Other SPECT Applications
-
-
2.2.2 PET Application
-
2.2.2.1 Oncology
-
2.2.2.2 Cardiology
-
2.2.2.3 Neurology
-
2.2.2.4 Other PET Applications
-
-
-
Spain Nuclear Imaging Market Size FAQs
How big is the Spain Nuclear Imaging Market?
The Spain Nuclear Imaging Market size is expected to reach USD 164.51 million in 2024 and grow at a CAGR of 2.78% to reach USD 188.68 million by 2029.
What is the current Spain Nuclear Imaging Market size?
In 2024, the Spain Nuclear Imaging Market size is expected to reach USD 164.51 million.